echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > China's first branch of green bonds in the field of biomedicine approved, public funds not more than 2 billion yuan

    China's first branch of green bonds in the field of biomedicine approved, public funds not more than 2 billion yuan

    • Last Update: 2020-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "
    Pharmaceutical Network Industry Dynamic" Recently, Chongqing High-tech Zone Development and Investment Group Co., Ltd("GaoKai Investment Group") declared the issuance of green bonds approved by the National Development and Reform CommissionIt is worth mentioning that the bond is also the country's first green bond in the field of biomedicineThe public fund raising does not exceed 2 billion yuan, of which 1 billion yuan will be raised for the chongqing high-tech development zone park recycling construction and transformation projects, and 1 billion yuan will be used to supplement the working capital of Gaokai Investment Groupit is understood that green bonds refer to enterprisebonds that raise funds to support energy-saving and emission reduction technology transformation, energy clean and efficient utilization, new energy development and utilization, circular economic development, water conservation and unconventional water resources development and utilization, ecological agriculture and forestry and other green cycle low-carbon development projectsthe fund-raising project of the green bonds of the Gaokai Investment Group is the project of recycling construction and transformation of the high-tech development zone park, and the project funds will support the infrastructure construction of the biopharmaceutical industry in the region, specifically for the construction of a new national biopharmaceutical base three-phase intensive plant, the construction of a centralized heating energy center, and will support the construction of sewage treatment plants, solid waste treatment centers and other environmental protection facilitiesAccording to the approval documents, Henyep Securities Co., Ltdwill act as the main underwriter of the bond issue, distributor Huaying Securities Co., Ltdwill form an underwriting group to underwrite the balance underwriting, the main work includes signing a debt and loan portfolio comprehensive financing service agreement with the issuer, providing the issuer with a reasonable integrated financial services plan for the duration of the bond, formulating the debt loan management plan, implementing the full management and dynamic risk monitoring of the issuer's debt financingBiomedicine is one of the strategic emerging industries in The Country, Chongqing High-tech Zone has always taken the biopharmaceutical industry as a key development industryIn the field of biomedicine, the high-tech zone takes project construction as the carrier, promotes the original technological innovation and re-creates new product research and development and industrialization, builds an innovation incubation platform, actively introduces leading pharmaceutical enterprises at home and abroad, innovates in new drug research and development, medical devices and other fields, and accelerates the cultivation of the biopharmaceutical industry as a new pillar industryOctober 12, 2019, Chongqing High-tech Zone signed 14 biopharmaceutical projects with a total investment of about 24.2 billion yuan, and the existing biopharmaceutical enterprises involved in medical devices, macromolecular drugs, cell immunotherapy, genetic testing and other sub-sectors, introduced more than 20 key projects such as Sino Pharmaceuticals, Sien Pharmaceutical Industry Base, Chinese Traditional Medicine, Chongqing Life Science and Technology Industrial Park, etcTaking this as an opportunity, Chongqing High-tech Zone gathered industry, technology, talent and capital, set up a biopharmaceutical industry fund, the construction of precision biomedicine, macromolecular drugs, in vitro diagnostic reagents (IVD) three public service platforms, the construction of the biopharmaceutical industry ecosystemaccording to the plan, the next step Chongqing High-tech Zone will integrate existing biopharmaceutical resources, around the field of medical devices, biopharmaceuticals, the construction of life science research and development base, explore precision testing, precision medicine and other cutting-edge life sciences fields, become the leading biopharmaceutical industry concentration area and life scienceindustry highlandsWith the approval of the green bond, it is conducive to giving full play to the professional market ability, effectively broaden the financing channels of enterprises, reduce the cost of financingAt the same time, it is expected to accelerate the recycling of construction and transformation, improve the competitiveness of the biopharmaceutical industry, promote the landing of excellent biopharmaceutical industry projects, accelerate the improvement of the biopharmaceutical industry chain.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.